To assess the contribution of Factor IX/IXa, to intravascular thrombosis, a canine coronary thrombosis model was studied. Thrombus formation was initiated by applying current to a needle in the circumflex coronary artery. When 50% occlusion of the vessel developed, the current was stopped and animals received an intravenous bolus of either saline, bovine glutamyl-glycyl-arginyl-Factor IXa (IXai), a competitive inhibitor of Factor IXa assembly into the intrinsic Factor X activation complex, bovine Factor IX, or heparin. Animals receiving saline or Factor IX developed coronary occlusion due to a fibrin/platelet thrombus in 70 +/- 11 min. In contrast, infusion of IXai prevented thrombus formation completely (greater than 180 min) at doses of 460 and 300 micrograms/kg, and partially blocked thrombus formation at 150 micrograms/kg. IXai attenuated the accumulation of 125I-fibrinogen/fibrin at the site of the thrombus by approximately 67% (P less than 0.001) and resulted in approximately 26% decrease in serotonin release from platelets in coronary sinus (P less than 0.05). Hemostatic variables in animals receiving IXai, remained within normal limits. Animals given heparin in a concentration sufficient to prevent occlusive thrombosis had markedly increased bleeding, whereas heparin levels that maintained extravascular hemostasis did not prevent intracoronary thrombosis. This suggests that Factor IX/IXa can contribute to thrombus formation, and that inhibition of IXa participation in the clotting mechanism blocks intravascular thrombosis without impairing extravascular hemostasis.
C R Benedict, J Ryan, B Wolitzky, R Ramos, M Gerlach, P Tijburg, D Stern
Title and authors | Publication | Year |
---|---|---|
Factor IX(a) inhibitors: an updated patent review (2003-present).
Afosah DK, Ofori E, Mottamal M, Al-Horani RA |
Expert Opinion on Therapeutic Patents | 2022 |
Immunodiagnostic Technologies from Laboratory to Point-Of-Care Testing
P Suman, P Chandra |
2020 | |
Translation and Clinical Development of Antithrombotic Aptamers
SM Nimjee, TJ Povsic, BA Sullenger, RC Becker |
Nucleic Acid Therapeutics (Formerly Oligonucleotides) | 2016 |
Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism
S Devabhakthuni, CH Yoon, KJ Pincus |
Journal of Pharmacy Practice | 2016 |
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial
AM Lincoff, R Mehran, TJ Povsic, SL Zelenkofske, Z Huang, PW Armstrong, PG Steg, C Bode, MG Cohen, C Buller, P Laanmets, M Valgimigli, T Marandi, V Fridrich, WJ Cantor, B Merkely, J Lopez-Sendon, JH Cornel, JD Kasprzak, M Aschermann, V Guetta, J Morais, PR Sinnaeve, K Huber, R Stables, MA Sellers, M Borgman, L Glenn, AI Levinson, RD Lopes, V Hasselblad, RC Becker, JH Alexander |
The Lancet | 2015 |
Vascular Medicine: A Companion to Braunwald's Heart Disease
P Libby |
Vascular Medicine: A Companion to Braunwald's Heart Disease | 2013 |
Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism
Y Buyue, TM Misenheimer, JP Sheehan |
Journal of Thrombosis and Haemostasis | 2012 |
The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome
JP Vavalle, MG Cohen |
Future Cardiology | 2012 |
Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates
WJ van Rensburg, JP Roodt, S Lamprecht, SM Meiring, PN Badenhorst |
Clinical and Experimental Medicine | 2012 |
Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs
H Ulrichts, K Silence, A Schoolmeester, P Jaegere, S Rossenu, J Roodt, S Priem, M Lauwereys, P Casteels, FV Bockstaele, K Verschueren, P Stanssens, J Baumeister, JB Holz |
Blood | 2011 |
Factor IXa as a Target for Pharmacologic Inhibition in Acute Coronary Syndrome
C Roser-Jones, M Chan, EL Howard, KC Becker, CP Rusconi, RC Becker |
Cardiovascular Therapeutics | 2011 |
Annual Reports in Medicinal Chemistry
JJ Liu, TW Lee |
Annual Reports in Medicinal Chemistry Volume 46 | 2011 |
Burger's Medicinal Chemistry and Drug Discovery
S Bruno, L Ronda, S Faggiano, S Bettati, A Mozzarelli |
Burger's Medicinal Chemistry and Drug Discovery | 2010 |
xPharm: The Comprehensive Pharmacology Reference
A Vinh |
xPharm: The Comprehensive Pharmacology Reference | 2010 |
Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite
Y Buyue, JP Sheehan |
Blood | 2009 |
Cardiovascular disease in patients with hemophilia
A Tuinenburg, EP Mauser-Bunschoten, MC Verhaar, DH Biesma, RE Schutgens |
Journal of Thrombosis and Haemostasis | 2009 |
Fundamental and Clinical Cardiology Series
PD Stein |
Cardiovascular Disease in the Elderly | 2008 |
Anticoagulant therapy during cardiopulmonary bypass
M Yavari, RC Becker |
Journal of Thrombosis and Thrombolysis | 2008 |
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor
MY Chan, CP Rusconi, JH Alexander, RM Tonkens, RA Harrington, RC Becker |
Journal of Thrombosis and Haemostasis | 2008 |
Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study
BI Eriksson, OE Dahl, MR Lassen, DP Ward, R Rothlein, G Davis, AG Turpie |
Journal of Thrombosis and Haemostasis | 2008 |
Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies
D Luan, M Zai, JD Varner, S Miyano |
PLoS computational biology | 2007 |
The status of new anticoagulants
SM Bates, JI Weitz |
British Journal of Haematology | 2006 |
Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism
JP Sheehan, EN Walke |
Blood | 2006 |
New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin
SM Bates, JI Weitz |
British Journal of Pharmacology | 2005 |
New anticoagulants
JI Weitz, SM Bates |
Journal of Thrombosis and Haemostasis | 2005 |
5-Amidinobenzo[b]thiophenes as dual inhibitors of factors IXa and Xa
JX Qiao, X Cheng, DP Modi, KA Rossi, JM Luettgen, RM Knabb, PK Jadhav, RR Wexler |
Bioorganic & Medicinal Chemistry Letters | 2005 |
Structure-based design and synthesis of pyrazinones containing novel P1 ‘side pocket’ moieties as inhibitors of TF/VIIa
BA Schweitzer, WL Neumann, HK Rahman, CL Kusturin, KR Sample, GI Poda, RG Kurumbail, AM Stevens, RA Stegeman, WC Stallings, MS South |
Bioorganic & Medicinal Chemistry Letters | 2005 |
The coagulation factor lottery – Is 9 the winning number?
GZ Feuerstein, D Stern |
Drug Discovery Today: Therapeutic Strategies | 2005 |
The Factor IXa Heparin-Binding Exosite Is a Cofactor Interactive Site: Mechanism for Antithrombin-Independent Inhibition of Intrinsic Tenase by Heparin
QP Yuan, EN Walke, JP Sheehan |
Biochemistry | 2005 |
Anticoagulant drugs: an update
HC Kwaan, MM Samama |
Expert Review of Cardiovascular Therapy | 2004 |
The impact of vitamin K-dependent factor depletion by warfarin on platelet-rich thrombosis after deep arterial injury
RD Mcbane, NL Hassinger, DE Grill, JH Chesebro |
Journal of Thrombosis and Haemostasis | 2004 |
Antidotes to haemorrhage: recombinant factor VIIa
CM Kessler |
Best Practice & Research Clinical Haematology | 2004 |
The Future of Anticoagulation
PP Dobesh, K Kim, Z Stacy |
Journal of Pharmacy Practice | 2004 |
Current anticoagulant therapy—unmet clinical needs
J Hirsh |
Thrombosis Research | 2003 |
Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation
K Kitazato, KT Kitazato, E Sasaki, K Minamiguchi, H Nagase |
Thrombosis Research | 2003 |
Inhibition of arterial thrombosis by polyamines in a canine coronary artery injury model
R Pakala |
Thrombosis Research | 2003 |
New Anticoagulants: Current Status and Future Potential
JI Weitz, MA Crowther |
American Journal Cardiovascular Drugs | 2003 |
Heparin Inhibits the Intrinsic Tenase Complex by Interacting with an Exosite on Factor IXa
JP Sheehan, CE Kobbervig, HM Kirkpatrick |
Biochemistry | 2003 |
Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke
JR Toomey, RE Valocik, PF Koster, MA Gabriel, M McVey, TK Hart, EH Ohlstein, AA Parsons, FC Barone |
Stroke; a journal of cerebral circulation | 2002 |
Antithrombotic agents in the treatment of severe sepsis
H Shadid, S Aziz, S Ahmad, J Fareed, D Hoppensteadt, H Messmore, W Wehrmacher, M Tobu, O Iqbal |
Expert Opinion on Emerging Drugs | 2002 |
Overview of anticoagulant drugs for the future
S Moll, HR Roberts |
Seminars in Hematology | 2002 |
Effect of polyamines on in vitro platelet aggregation and in vivo thrombus formation
R Pakala |
Cardiovascular Radiation Medicine | 2002 |
A Human Antibody That Inhibits Factor IX/IXa Function Potently Inhibits Arterial Thrombosis Without Increasing Bleeding
CJ Refino, S Jeet, L DeGuzman, S Bunting, D Kirchhofer |
Arteriosclerosis, thrombosis, and vascular biology | 2002 |
Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model
I Singh, A Smith, B Vanzieleghem, D Collen, K Burnand, JM Saint-Remy, M Jacquemin |
Blood | 2002 |
Emerging anticoagulant and thrombolytic drugs
O Iqbal, S Aziz, DA Hoppensteadt, S Ahmad, JM Walenga, M Bakhos, J Fareed |
Expert Opinion on Emerging Drugs | 2001 |
Factor IX and thrombosis
GD Lowe |
British Journal of Haematology | 2001 |
New Anticoagulant Drugs
JI Weitz, J Hirsh |
Chest | 2001 |
New anticoagulant drugs
J I Weitz |
Journal of Thrombosis and Thrombolysis | 2001 |
Comparing the Antithrombotic Efficacy of a Humanized Anti-factor IX(a) Monoclonal Antibody (SB 249417) to the Low Molecular Weight Heparin Enoxaparin In a Rat Model of Arterial Thrombosis
JR Toomey, MN Blackburn, BL Storer, RE Valocik, PF Koster, GZ Feuerstein |
Thrombosis Research | 2000 |
Hypersulfated Low Molecular Weight Heparin with Reduced Affinity for Antithrombin Acts as an Anticoagulant by Inhibiting Intrinsic Tenase and Prothrombinase
JA Anderson, JC Fredenburgh, AR Stafford, YS Guo, J Hirsh, V Ghazarossian, JI Weitz |
The Journal of biological chemistry | 2000 |
Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism
JE Ansell, JI Weitz, AJ Comerota |
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 2000 |
Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage
TF Choudhri, BL Hoh, CJ Prestigiacomo, J Huang, LJ Kim, AM Schmidt, W Kisiel, ES Connolly, DJ Pinsky |
Journal of Experimental Medicine | 1999 |
Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats
GZ Feuerstein, A Patel, JR Toomey, P Bugelski, AJ Nichols, WR Church, R Valocik, P Koster, A Baker, MN Blackburn |
Arteriosclerosis, thrombosis, and vascular biology | 1999 |
Antithrombotics
AC Uprichard, KP Gallagher |
1999 | |
THERAPEUTIC INHIBITION OF THROMBIN ACTIVITIES, RECEPTORS, AND PRODUCTION
LA Harker |
Hematology/Oncology Clinics of North America | 1998 |
Management of Bleeding Complications in Redo Cardiac Operations
CR MD |
The Annals of Thoracic Surgery | 1998 |
Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass
T B Spanier, J M Chen, M C Oz, N M Edwards, W Kisiel, D M Stern, E A Rose, A M Schmidt |
The Journal of Thoracic and Cardiovascular Surgery | 1998 |
Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog
T B Spanier, M C Oz, O P Minanov, R Simantov, W Kisiel, D M Stern, E A Rose, A M Schmidt |
The Journal of Thoracic and Cardiovascular Surgery | 1998 |
Textbook of Coronary Thrombosis and Thrombolysis
RC Becker |
1997 | |
Novel antithrombotic strategies for the treatment of coronary artery thrombosis: A critical appraisal
PR Eisenberg |
Journal of Thrombosis and Thrombolysis | 1995 |
Calreticulin, an Antithrombotic Agent Which Binds to Vitamin K-dependent Coagulation Factors, Stimulates Endothelial Nitric Oxide Production, and Limits Thrombosis in Canine Coronary Arteries
K Kuwabara, DJ Pinsky, AM Schmidt, B Benedict, B Brett, S Ogawa, MJ Broekman, AJ Marcus, RR Sciacca, M Michalak, F Wang, YC Pan, G Grunfeld, P Patton, T Malinski, DM Stern, J Ryan |
The Journal of biological chemistry | 1995 |
New Variant of Human Tissue Plasminogen Activator (TPA) With Enhanced Efficacy and Lower Incidence of Bleeding Compared With Recombinant Human TPA
CR Benedict, CJ Refino, BA Keyt, R Pakala, NF Paoni, GR Thomas, WF Bennett |
Circulation | 1995 |
Active Site–Blocked Factors VIIa and IXa Differentially Inhibit Fibrin Formation in a Human Ex Vivo Thrombosis Model
D Kirchhofer, TB Tschopp, HR Baumgartner |
Arteriosclerosis, thrombosis, and vascular biology | 1995 |
Macromolecular Complex Assembly of Prothrombinase Is a Central Process of Thrombosis
U Sinha, S Hollenbach, DL Wolf |
Annals of the New York Academy of Sciences | 1994 |
Endothelial-dependent procoagulant and anticoagulant mechanisms. Recent advances in understanding
CR Benedict, R Pakala, JT Willerson |
Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital | 1994 |
Platelet membrane-mediated coagulation protease complex assembly
SS Ahmad, PN Walsh |
Trends in Cardiovascular Medicine | 1994 |
High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury
JK Mickelson, PT Hoff, JW Homeister, JC Fantone, BR Lucchesi |
Journal of the American College of Cardiology | 1993 |
Enhancement of recombinant tissue plasminogen activator-induced reperfusion by recombinant tick anticoagulant peptide, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis
MJ Mellott, MT Stranieri, GR Sitko, II Stabilito, JJ Lynch, GP Vlasuk |
Fibrinolysis | 1993 |
Calreticulin
M Michalak, RE Milner, K Burns, M Opas |
Biochemical Journal | 1992 |
Expression, purification, and characterization of inactive human coagulation factor Xa (Asn322Ala419)
U Sinha, TE Hancock, PH Lin, S Hollenbach, DL Wolfs |
Protein Expression and Purification | 1992 |